253 results
8-K
EX-99.1
GOVX
Geovax Labs Inc
6 May 20
GeoVax Reports 2020 First Quarter Financial Results
5:26pm
three vaccine candidates for COVID-19. Safety, efficacy, and durability of protection (long-lasting) are the expected characteristics of our GV-MVA … -VLPTM vaccine platform being used for constructing our vaccines. Our platform has a track record of safety in humans through our HIV vaccine program
8-K
EX-99
GOVX
Geovax Labs Inc
25 Jun 07
GeoVax Contracts Althea Technologies for Phase 2 AIDS Vaccine Production
12:00am
Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus components but can’t cause AIDS. Safety and immunological results from earlier … Results
Ongoing GeoVax preventive HIV/AIDS vaccine human trials indicated:
Very acceptable safety profiles in 1/10th dose trials started April 2006
1
8-K
EX-99
GOVX
Geovax Labs Inc
3 Jul 07
Other Events
12:00am
began in April 2003 to evaluate safety and efficacy of both its DNA & MVA anti-HIV [AIDS] vaccines. To date, one trial has successfully concluded, 2 … are ongoing since 2006, and 2 additional trials are slated to begin July 2007. Encouraging safety and immunological results from these Phase 1 trials
8-K
EX-99
GOVX
Geovax Labs Inc
17 Jul 07
GeoVax Announces Start of 2 New HIV/AIDS Vaccine Human Trials
12:00am
intended to evaluate both human safety and immune responses to GeoVax’s HIV/AIDS vaccines.
GeoVax’s vaccines are designed to prevent Acquired … ) vaccination program. Preliminary results from this blinded trial demonstrated excellent vaccine safety and positive anti-HIV-1 immune responses
DEFA14A
GOVX
Geovax Labs Inc
7 Jul 20
Additional proxy soliciting materials
12:00am
challenge testing. Our platform has a track record of safety in humans through our HIV vaccine program and the preclinical testing results we have seen … .
From here, we will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy observed when we conclude our animal
8-K
EX-99
e8iac0
14 Mar 08
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
12:00am
8-K
EX-99.1
1ivgd0t51
6 Aug 10
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
0vp wzbxasakz61hxkz
15 Dec 21
GeoVax Announces Initiation of Phase 2 Clinical Trial
4:11pm
8-K
EX-99.1
c89tuhef
10 Oct 13
Other Events
12:00am
8-K
EX-99.1
z1g0is95a4z
10 Aug 20
GeoVax Reports 2020 Second Quarter Financial Results
2:02pm
8-K
EX-99.1
3bpa2oh
24 Jan 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
7jdb32opn 9th8
31 Mar 10
Geovax Labs Granted Allowance by Fda to Start Phase 1 Clinical Trial for Hiv/aids Therapeutic Vaccine
12:00am
8-K
EX-99.1
lj1bkef0 8hl
2 May 13
GeoVax Labs Reports 2013 First Quarter Financial Results
12:00am
8-K
EX-99.1
qubht94yv2k3 g0h
10 Mar 22
GeoVax Reports 2021 Year-End Financial Results
5:02pm
8-K
EX-99.1
xj87corb d7z7h
13 Aug 13
GeoVax Reports Financial Results for the Second Quarter
12:00am
8-K
EX-99.1
nrrycg8c op
12 Mar 13
GeoVax Labs Reports 2012 Financial Results and Progress
12:00am
8-K
EX-99.1
cnsohsyizqbxf4ty5eva
22 Mar 10
Geovax Labs Appoints Two Industry Veterans to Board of Directors
12:00am
8-K
EX-99.1
kzs1pe3
10 Nov 11
Announces Nine Month 2011 Financial Results
12:00am
8-K
EX-99.1
5opzzr
12 Nov 21
GeoVax Reports 2021 Third Quarter Financial Results
1:37pm